HT
PCVX icon

Headlands Technologies’s Vaxcyte PCVX Stock Holding History

Headlands Technologies’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,102
Closed -$238K – 926
2026
Q1 		$238K Sell
4,102
-27,604
-87% -$1.5M 0.03% 562
2025
Q4 		$1.46M Sell
31,706
-1,025
-3% -$45.8K 0.12% 203
2025
Q3 		$1.18M Buy
32,731
+5,738
+21% +$190K 0.09% 208
2025
Q2 		$878K Buy
26,993
+2,941
+12% +$96.4K 0.11% 207
2025
Q1 		$908K Sell
24,052
-15,365
-39% -$1.23M 0.1% 202
2024
Q4 		$3.23M Buy
39,417
+11,635
+42% +$1.16M 0.32% 73
2024
Q3 		$3.17M Buy
+27,782
New +$2.5M 0.37% 58

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Headlands Technologies's PCVX Position: Q2 2026 in Review

Headlands Technologies sold out of Vaxcyte (PCVX) in Q2 2026, closing a stake of 4,102 shares — an estimated $238K sold.

Headlands Technologies first reported a position in PCVX in Q3 2024 and held it in 7 quarters. The position peaked at $3.23M in Q4 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Headlands Technologies reported no remaining Vaxcyte position as of Q2 2026 after selling out during the quarter.
  • Headlands Technologies sold 4,102 Vaxcyte shares in Q2 2026, an estimated $238K.
  • Headlands Technologies first reported a position in Vaxcyte in Q3 2024 and held it in 7 quarters.
  • Headlands Technologies's Vaxcyte position peaked at $3.23M in Q4 2024.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.